Efficacy and safety of emapalumab in macrophage activation syndrome.
Journal Information
Full Title: Ann Rheum Dis
Abbreviation: Ann Rheum Dis
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Competing interests: FDB: consultant and research grants from AbbVie, Sobi, Pfizer, Roche, Sanofi, Novartis, Novimmune; AAG: consultant for Novartis, AB2 Bio, Novimmune, Sobi; PAB: consultant for Sobi, Novartis, Roche, UCB; CB, MP, GM: none declared; DE: speaker bureau for Sobi; CP: speaker bureau for Sobi; GS: consultant for Novartis, Sobi, Novimmune, AB2 Bio; PQ: consultant for AbbVie, Chugai-Roche, Lilly, Novartis, Pfizer, Sobi and speaker bureau for AbbVie, Chugai-Roche, Lilly, Novartis, Pfizer, Sobi; JA: consultant for Sobi, Novartis, Roche, Pfizer, AbbVie, GSK; CL: consultant for Sobi; RF: previously employed by Sobi; VA: previously employed by Sobi; MB: previously employed by Sobi; PJ: consultant for Sobi; CdM: consultant for Sobi, previously employed by Sobi."
"Funding: NI-0501-05 and NI-0501-06 (ClinicalTrials.gov numbers, NCT02069899 and NCT03311854) were funded by Sobi."
"Trial registration number NCT02069899 and NCT03311854."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025